A Phase Ib Study of Selinexor in Combination with Pembrolizumab in Patients with Metastatic Melanoma

Introduction: Immune checkpoint inhibitors (ICIs) have substantially advanced the treatment of patients with malignant melanoma. However, improving therapeutic efficacy requires identifying drug combinations that elicit durable responses without inducing intolerable toxicity. Within that context, se...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής

Κύριοι συγγραφείς:	Mohamed A. Gouda, Bettzy Stephen, Yanyan Tian, Anas Alshawa, Dilichukwu O. Chudy Onwugaje, Aya Albittar, Yali Yang, Abdulrazzak Zarifa, Bulent Yilmaz, Serdar Gurses, Ashabari Sprenger, Mohamed H. Derbala, Amanda Brink, Jeffrey Andrew How, Justin Moyers, Sarina A. Piha-Paul, David S. Hong, Funda Meric-Bernstam, Sapna P. Patel, Isabella Glitza Oliva
Μορφή:	Artigo
Γλώσσα:	Inglês
Έκδοση:	Innovative Healthcare Institute 2024-11-01
Σειρά:	Journal of Immunotherapy and Precision Oncology
Θέματα:	selinexor immune checkpoint inhibitors melanoma
Διαθέσιμο Online:	https://jipo.org/doi/pdf/10.36401/JIPO-24-3
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!